Cargando…
Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta-analysis of randomized controlled trials
Previous studies have shown that the combination of cilostazol and aspirin may be a more effective regimen than ticlopidine plus aspirin in the prevention of late restenosis and acute or subacute stent thrombosis following coronary stenting; however, individually published results are inconclusive....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786799/ https://www.ncbi.nlm.nih.gov/pubmed/24137273 http://dx.doi.org/10.3892/etm.2013.1190 |
_version_ | 1782477774744715264 |
---|---|
author | HU, FENG-HUAN YI, XIN YANG, YUE-JING QIAO, SHU-BIN WU, YONG-JIAN YUAN, JIAN-SONG |
author_facet | HU, FENG-HUAN YI, XIN YANG, YUE-JING QIAO, SHU-BIN WU, YONG-JIAN YUAN, JIAN-SONG |
author_sort | HU, FENG-HUAN |
collection | PubMed |
description | Previous studies have shown that the combination of cilostazol and aspirin may be a more effective regimen than ticlopidine plus aspirin in the prevention of late restenosis and acute or subacute stent thrombosis following coronary stenting; however, individually published results are inconclusive. The aim of this meta-analysis was to compare the differences in late restenosis and stent thrombosis between cilostazol plus aspirin and ticlopidine plus aspirin for patients with coronary heart disease (CHD) following coronary stenting. A literature search of Pubmed, Embase, Web of Science and Chinese BioMedicine (CBM) databases was conducted from 1998 to March 1, 2013 and statistical analysis was performed using Stata statistical software, version 12.0. Twelve randomized controlled trials were included in the study, with a total of 2,708 patients with CHD following coronary stenting. The patient population comprised 1,371 patients treated with cilostazol plus aspirin and 1,337 patients treated with ticlopidine plus aspirin. The meta-analysis showed that cilostazol plus aspirin demonstrated a lower rate of restenosis than ticlopidine plus aspirin [odds ratio (OR)=0.83, 95% confidence interval (CI)=0.69–0.99, P=0.047]. A significant difference was also observed in the average percent diameter stenosis between cilostazol plus aspirin and ticlopidine plus aspirin [standardized weight difference (SMD)= −0.57, 95% CI=−0.92, −0.23, P=0.001). However, there were no significant differences in the rates of acute or subacute stent thrombosis between cilostazol plus aspirin and ticlopidine plus aspirin. The present meta-analysis suggests that cilostazol plus aspirin may result in a lower restenosis rate and percent diameter stenosis than ticlopidine plus aspirin for patients with CHD following coronary stenting. |
format | Online Article Text |
id | pubmed-3786799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-37867992013-10-17 Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta-analysis of randomized controlled trials HU, FENG-HUAN YI, XIN YANG, YUE-JING QIAO, SHU-BIN WU, YONG-JIAN YUAN, JIAN-SONG Exp Ther Med Articles Previous studies have shown that the combination of cilostazol and aspirin may be a more effective regimen than ticlopidine plus aspirin in the prevention of late restenosis and acute or subacute stent thrombosis following coronary stenting; however, individually published results are inconclusive. The aim of this meta-analysis was to compare the differences in late restenosis and stent thrombosis between cilostazol plus aspirin and ticlopidine plus aspirin for patients with coronary heart disease (CHD) following coronary stenting. A literature search of Pubmed, Embase, Web of Science and Chinese BioMedicine (CBM) databases was conducted from 1998 to March 1, 2013 and statistical analysis was performed using Stata statistical software, version 12.0. Twelve randomized controlled trials were included in the study, with a total of 2,708 patients with CHD following coronary stenting. The patient population comprised 1,371 patients treated with cilostazol plus aspirin and 1,337 patients treated with ticlopidine plus aspirin. The meta-analysis showed that cilostazol plus aspirin demonstrated a lower rate of restenosis than ticlopidine plus aspirin [odds ratio (OR)=0.83, 95% confidence interval (CI)=0.69–0.99, P=0.047]. A significant difference was also observed in the average percent diameter stenosis between cilostazol plus aspirin and ticlopidine plus aspirin [standardized weight difference (SMD)= −0.57, 95% CI=−0.92, −0.23, P=0.001). However, there were no significant differences in the rates of acute or subacute stent thrombosis between cilostazol plus aspirin and ticlopidine plus aspirin. The present meta-analysis suggests that cilostazol plus aspirin may result in a lower restenosis rate and percent diameter stenosis than ticlopidine plus aspirin for patients with CHD following coronary stenting. D.A. Spandidos 2013-09 2013-07-01 /pmc/articles/PMC3786799/ /pubmed/24137273 http://dx.doi.org/10.3892/etm.2013.1190 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles HU, FENG-HUAN YI, XIN YANG, YUE-JING QIAO, SHU-BIN WU, YONG-JIAN YUAN, JIAN-SONG Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta-analysis of randomized controlled trials |
title | Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta-analysis of randomized controlled trials |
title_full | Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta-analysis of randomized controlled trials |
title_fullStr | Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta-analysis of randomized controlled trials |
title_full_unstemmed | Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta-analysis of randomized controlled trials |
title_short | Comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: A meta-analysis of randomized controlled trials |
title_sort | comparison of cilostazol versus ticlopidine following coronary stenting in patients with coronary heart disease: a meta-analysis of randomized controlled trials |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786799/ https://www.ncbi.nlm.nih.gov/pubmed/24137273 http://dx.doi.org/10.3892/etm.2013.1190 |
work_keys_str_mv | AT hufenghuan comparisonofcilostazolversusticlopidinefollowingcoronarystentinginpatientswithcoronaryheartdiseaseametaanalysisofrandomizedcontrolledtrials AT yixin comparisonofcilostazolversusticlopidinefollowingcoronarystentinginpatientswithcoronaryheartdiseaseametaanalysisofrandomizedcontrolledtrials AT yangyuejing comparisonofcilostazolversusticlopidinefollowingcoronarystentinginpatientswithcoronaryheartdiseaseametaanalysisofrandomizedcontrolledtrials AT qiaoshubin comparisonofcilostazolversusticlopidinefollowingcoronarystentinginpatientswithcoronaryheartdiseaseametaanalysisofrandomizedcontrolledtrials AT wuyongjian comparisonofcilostazolversusticlopidinefollowingcoronarystentinginpatientswithcoronaryheartdiseaseametaanalysisofrandomizedcontrolledtrials AT yuanjiansong comparisonofcilostazolversusticlopidinefollowingcoronarystentinginpatientswithcoronaryheartdiseaseametaanalysisofrandomizedcontrolledtrials |